Strides Says Makeover On Track, Raises EBITDA Guidance
Strides Shasun founder and serial dealmaker Arun Kumar, who’s been bulking up on new acquisitions as he steers the major Indian drug company into a new avatar, says group consolidation is on track and has upped EBITDA guidance after strong second-quarter earnings.
You may also be interested in...
Strides Shasun has reported third-quarter net profit plunged by 57% but the Indian firm says performance will improve in coming quarters thanks to its regulated market focus, and analysts agree earnings look set to rise.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.